Biogen's ALS drug falters in Phase 3 trials

The antisense drug tofersen failed to improve symptoms of the neurodegenerative disease, but the company wants to expand access to it anyway

Source: Chemical and Engineering News - October 20, 2021 Category: Chemistry Authors: Megha Satyanarayana Source Type: research